---
document_datetime: 2025-12-02 06:00:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vizimpro.html
document_name: vizimpro.html
version: success
processing_time: 0.1064333
conversion_datetime: 2025-12-28 11:41:05.351491
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vizimpro

[RSS](/en/individual-human-medicine.xml/67184)

##### Authorised

This medicine is authorised for use in the European Union

dacomitinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vizimpro](#news-on)
- [More information on Vizimpro](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vizimpro is a cancer medicine used to treat adults with non small cell lung cancer (NSCLC) when the disease is advanced or has spread.

Vizimpro is used on its own and only in patients with certain mutations (changes) in the gene for a protein called epidermal growth factor receptor (EGFR).

Vizimpro contains the active substance dacomitinib.

Expand section

Collapse section

## How is Vizimpro used?

Vizimpro is available as tablets (15, 30 and 45 mg). The patient should normally take a 45-mg tablet once a day, at around the same time every day, for as long as they benefit from it and the side effects are tolerable. If certain side effects develop the doctor may decide to reduce the dose or stop treatment.

Vizimpro can only be obtained with a prescription and treatment must be started and supervised by a doctor with experience in using cancer medicines. Before starting treatment, the presence of mutations in the EGFR gene should be confirmed by appropriate tests.

For more information about using Vizimpro, see the package leaflet or contact your doctor or pharmacist.

## How does Vizimpro work?

The active substance in Vizimpro, dacomitinib, belongs to a group of cancer medicine called tyrosine kinase inhibitor. It blocks the activity of EGFR, which normally controls growth and division of cells. In lung cancer cells, EGFR is often overactive, causing uncontrolled growth of cancer cells. By blocking EGFR, dacomitinib helps to reduce the growth and spread of the cancer.

## What benefits of Vizimpro have been shown in studies?

Vizimpro has been shown to be more effective than gefitinib (another medicine for non-small cell lung cancer) at prolonging the time patients lived without their disease getting worse. In one main study involving 452 patients with EGFR mutations, patients given Vizimpro lived on average for around 15 months without their disease getting worse, compared with 9 months for those given gefitinib.

## What are the risks associated with Vizimpro?

The most common side effects with Vizimpro (which may affect more than 1 in 5 people) are diarrhoea, rash, stomatitis (inflammation of the lining of the mouth), nail disorder, dry skin, loss of appetite, conjuntivitis (redness and discomfort in the eye), weight and hair loss, itching, elevated levels of transaminases (a sign of liver problems) and nausea (feeling sick). The most frequent serious side effects are diarrhoea, interstitial lung disease (disorders causing scarring in the lungs), rash and loss of appetite.

For the full list of side effects and restrictions of Vizimpro, see the package leaflet.

## Why is Vizimpro authorised in the EU?

Vizimpro was shown to significantly improve the length of time patients lived without their disease getting worse. Patients taking Vizimpro lived for an extra 6 months without their disease getting worse compared with those taking gefitinib. Although Vizimpro caused more side effects than gefitinib, these were considered manageable. The European Medicines Agency therefore decided that Vizimpro's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Vizimpro?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vizimpro have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vizimpro are continuously monitored. Side effects reported with Vizimpro are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vizimpro

Vizimpro received a marketing authorisation valid throughout the EU on 2 April 2019.

Vizimpro : EPAR - Medicine overview

Reference Number: EMA/89209/2019

English (EN) (107.59 KB - PDF)

**First published:** 05/06/2019

[View](/en/documents/overview/vizimpro-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-618)

български (BG) (101.06 KB - PDF)

**First published:**

05/06/2019

[View](/bg/documents/overview/vizimpro-epar-medicine-overview_bg.pdf)

español (ES) (105.55 KB - PDF)

**First published:**

05/06/2019

[View](/es/documents/overview/vizimpro-epar-medicine-overview_es.pdf)

čeština (CS) (97.48 KB - PDF)

**First published:**

05/06/2019

[View](/cs/documents/overview/vizimpro-epar-medicine-overview_cs.pdf)

dansk (DA) (105.22 KB - PDF)

**First published:**

05/06/2019

[View](/da/documents/overview/vizimpro-epar-medicine-overview_da.pdf)

Deutsch (DE) (110.06 KB - PDF)

**First published:**

05/06/2019

[View](/de/documents/overview/vizimpro-epar-medicine-overview_de.pdf)

eesti keel (ET) (104.31 KB - PDF)

**First published:**

05/06/2019

[View](/et/documents/overview/vizimpro-epar-medicine-overview_et.pdf)

ελληνικά (EL) (118.2 KB - PDF)

**First published:**

05/06/2019

[View](/el/documents/overview/vizimpro-epar-medicine-overview_el.pdf)

français (FR) (74.64 KB - PDF)

**First published:**

05/06/2019

[View](/fr/documents/overview/vizimpro-epar-medicine-overview_fr.pdf)

hrvatski (HR) (107.74 KB - PDF)

**First published:**

05/06/2019

[View](/hr/documents/overview/vizimpro-epar-medicine-overview_hr.pdf)

italiano (IT) (107.53 KB - PDF)

**First published:**

05/06/2019

[View](/it/documents/overview/vizimpro-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (95.4 KB - PDF)

**First published:**

05/06/2019

[View](/lv/documents/overview/vizimpro-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (94.79 KB - PDF)

**First published:**

05/06/2019

[View](/lt/documents/overview/vizimpro-epar-medicine-overview_lt.pdf)

magyar (HU) (109.95 KB - PDF)

**First published:**

05/06/2019

[View](/hu/documents/overview/vizimpro-epar-medicine-overview_hu.pdf)

Malti (MT) (99.53 KB - PDF)

**First published:**

05/06/2019

[View](/mt/documents/overview/vizimpro-epar-medicine-overview_mt.pdf)

Nederlands (NL) (73.57 KB - PDF)

**First published:**

05/06/2019

[View](/nl/documents/overview/vizimpro-epar-medicine-overview_nl.pdf)

polski (PL) (97.8 KB - PDF)

**First published:**

05/06/2019

[View](/pl/documents/overview/vizimpro-epar-medicine-overview_pl.pdf)

português (PT) (73.77 KB - PDF)

**First published:**

05/06/2019

[View](/pt/documents/overview/vizimpro-epar-medicine-overview_pt.pdf)

română (RO) (94.72 KB - PDF)

**First published:**

05/06/2019

[View](/ro/documents/overview/vizimpro-epar-medicine-overview_ro.pdf)

slovenčina (SK) (96.06 KB - PDF)

**First published:**

05/06/2019

[View](/sk/documents/overview/vizimpro-epar-medicine-overview_sk.pdf)

slovenščina (SL) (91.77 KB - PDF)

**First published:**

05/06/2019

[View](/sl/documents/overview/vizimpro-epar-medicine-overview_sl.pdf)

Suomi (FI) (73.22 KB - PDF)

**First published:**

05/06/2019

[View](/fi/documents/overview/vizimpro-epar-medicine-overview_fi.pdf)

svenska (SV) (106.29 KB - PDF)

**First published:**

05/06/2019

[View](/sv/documents/overview/vizimpro-epar-medicine-overview_sv.pdf)

Vizimpro : EPAR - Risk-management-plan summary

English (EN) (89.74 KB - PDF)

**First published:** 05/06/2019

**Last updated:** 22/02/2021

[View](/en/documents/rmp-summary/vizimpro-epar-risk-management-plan-summary_en.pdf)

## Product information

Vizimpro : EPAR - Product information

English (EN) (328.62 KB - PDF)

**First published:** 05/06/2019

**Last updated:** 17/12/2024

[View](/en/documents/product-information/vizimpro-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-983)

български (BG) (381.38 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/bg/documents/product-information/vizimpro-epar-product-information_bg.pdf)

español (ES) (357.5 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/es/documents/product-information/vizimpro-epar-product-information_es.pdf)

čeština (CS) (368.58 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/cs/documents/product-information/vizimpro-epar-product-information_cs.pdf)

dansk (DA) (355.21 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/da/documents/product-information/vizimpro-epar-product-information_da.pdf)

Deutsch (DE) (340.39 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/de/documents/product-information/vizimpro-epar-product-information_de.pdf)

eesti keel (ET) (346.28 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/et/documents/product-information/vizimpro-epar-product-information_et.pdf)

ελληνικά (EL) (393.19 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/el/documents/product-information/vizimpro-epar-product-information_el.pdf)

français (FR) (360 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/fr/documents/product-information/vizimpro-epar-product-information_fr.pdf)

hrvatski (HR) (361.82 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/hr/documents/product-information/vizimpro-epar-product-information_hr.pdf)

íslenska (IS) (356.63 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/is/documents/product-information/vizimpro-epar-product-information_is.pdf)

italiano (IT) (352.45 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/it/documents/product-information/vizimpro-epar-product-information_it.pdf)

latviešu valoda (LV) (366.99 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/lv/documents/product-information/vizimpro-epar-product-information_lv.pdf)

lietuvių kalba (LT) (364.67 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/lt/documents/product-information/vizimpro-epar-product-information_lt.pdf)

magyar (HU) (366.55 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/hu/documents/product-information/vizimpro-epar-product-information_hu.pdf)

Malti (MT) (399.97 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/mt/documents/product-information/vizimpro-epar-product-information_mt.pdf)

Nederlands (NL) (364.7 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/nl/documents/product-information/vizimpro-epar-product-information_nl.pdf)

norsk (NO) (363.37 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/no/documents/product-information/vizimpro-epar-product-information_no.pdf)

polski (PL) (380.55 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/pl/documents/product-information/vizimpro-epar-product-information_pl.pdf)

português (PT) (348.46 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/pt/documents/product-information/vizimpro-epar-product-information_pt.pdf)

română (RO) (364.34 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/ro/documents/product-information/vizimpro-epar-product-information_ro.pdf)

slovenčina (SK) (372.09 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/sk/documents/product-information/vizimpro-epar-product-information_sk.pdf)

slovenščina (SL) (352.22 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/sl/documents/product-information/vizimpro-epar-product-information_sl.pdf)

Suomi (FI) (364.21 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/fi/documents/product-information/vizimpro-epar-product-information_fi.pdf)

svenska (SV) (339.78 KB - PDF)

**First published:**

05/06/2019

**Last updated:**

17/12/2024

[View](/sv/documents/product-information/vizimpro-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0012 11/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vizimpro : EPAR - All authorised presentations

English (EN) (28.24 KB - PDF)

**First published:** 05/06/2019

[View](/en/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-582)

български (BG) (30.45 KB - PDF)

**First published:**

05/06/2019

[View](/bg/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_bg.pdf)

español (ES) (27.82 KB - PDF)

**First published:**

05/06/2019

[View](/es/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_es.pdf)

čeština (CS) (28.49 KB - PDF)

**First published:**

05/06/2019

[View](/cs/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (28.92 KB - PDF)

**First published:**

05/06/2019

[View](/da/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (29.51 KB - PDF)

**First published:**

05/06/2019

[View](/de/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (28 KB - PDF)

**First published:**

05/06/2019

[View](/et/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (30.42 KB - PDF)

**First published:**

05/06/2019

[View](/el/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_el.pdf)

français (FR) (25.79 KB - PDF)

**First published:**

05/06/2019

[View](/fr/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (27.91 KB - PDF)

**First published:**

05/06/2019

[View](/hr/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (28.2 KB - PDF)

**First published:**

05/06/2019

[View](/is/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_is.pdf)

italiano (IT) (28.06 KB - PDF)

**First published:**

05/06/2019

[View](/it/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (28.68 KB - PDF)

**First published:**

05/06/2019

[View](/lv/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (29.59 KB - PDF)

**First published:**

05/06/2019

[View](/lt/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (28.64 KB - PDF)

**First published:**

05/06/2019

[View](/hu/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (28.58 KB - PDF)

**First published:**

05/06/2019

[View](/mt/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (27.86 KB - PDF)

**First published:**

05/06/2019

[View](/nl/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (28.9 KB - PDF)

**First published:**

05/06/2019

[View](/no/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_no.pdf)

polski (PL) (29.26 KB - PDF)

**First published:**

05/06/2019

[View](/pl/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_pl.pdf)

português (PT) (28.39 KB - PDF)

**First published:**

05/06/2019

[View](/pt/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_pt.pdf)

română (RO) (28.49 KB - PDF)

**First published:**

05/06/2019

[View](/ro/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (28.66 KB - PDF)

**First published:**

05/06/2019

[View](/sk/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (27.83 KB - PDF)

**First published:**

05/06/2019

[View](/sl/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (28.08 KB - PDF)

**First published:**

05/06/2019

[View](/fi/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (28.28 KB - PDF)

**First published:**

05/06/2019

[View](/sv/documents/all-authorised-presentations/vizimpro-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vizimpro Active substance dacomitinib monohydrate International non-proprietary name (INN) or common name dacomitinib Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01EB07

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.

## Authorisation details

EMA product number EMEA/H/C/004779 Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 31/01/2019 Marketing authorisation issued 02/04/2019 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vizimpro : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (116.79 KB - PDF)

**First published:** 22/02/2021

**Last updated:** 17/12/2024

[View](/en/documents/procedural-steps-after/vizimpro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Vizimpro : EPAR - Public assessment report

Reference Number: EMA/201148/2019

English (EN) (7.06 MB - PDF)

**First published:** 05/06/2019

[View](/en/documents/assessment-report/vizimpro-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vizimpro

Adopted

Reference Number: EMA/CHMP/34937/2019

English (EN) (104.56 KB - PDF)

**First published:** 01/02/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vizimpro_en.pdf)

#### News on Vizimpro

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019) 01/02/2019

#### More information on Vizimpro

- [ARIA: Real-world utilization and outcomes with dacomitinib first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients - A multi center chart review (A7471067) - post-authorisation study](https://catalogues.ema.europa.eu/study/44544)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 17/12/2024

## Share this page

[Back to top](#main-content)